SS-31 Dosage Guide & Peptide Benefits

Overview

SS-31, also known as elamipretide, is a mitochondria-targeting peptide best discussed through the lens of clinical evidence, labeled use, and careful medical supervision. In the United States, elamipretide is approved under the brand name FORZINITY for improving muscle strength in adults and children with Barth syndrome who weigh at least 30 kg, with once-daily subcutaneous dosing. This guide explains the current SS-31 dosage information in a practical, text-based format while keeping the focus on safety, evidence, and realistic expectations. (fda.gov)

What is the recommended SS-31 dosage?

The FDA-labeled SS-31 dosage for eligible Barth syndrome patients weighing at least 30 kg is 40 mg injected subcutaneously once daily, taken at the same time each day. Adults with severe renal impairment, defined in the label as eGFR less than 30 mL/minute and not on dialysis, have a reduced recommended dose of 20 mg once daily. This is prescription medical dosing, not a general wellness protocol, and it should not be copied for self-directed use. (accessdata.fda.gov)

Because many people search for "ss-31 peptide dosage," "ss31 peptide dosage," or "ss-31 peptide dose per day" outside a prescription context, it is important to separate labeled dosing from internet peptide protocols. Research chemicals, compounded products, and non-prescribed versions may differ in quality, concentration, sterility, and legal status. A clinician should determine whether elamipretide is appropriate, how it should be administered, and what monitoring is needed.

SS-31 peptide dosage chart

The following chart summarizes dosage information from the FDA label and related clinical-use guidance. It is intended for education and discussion with a licensed healthcare professional, not as a personal dosing plan.

Patient Group	Dose	Route	Timing	Use Guideline
Eligible Barth syndrome (>=30 kg)	40 mg once daily	Subcutaneous injection	Same time each day	Labeled dose for adults and pediatric patients meeting weight requirement
Mild or moderate renal impairment	40 mg once daily	Subcutaneous injection	Same time each day	No dose adjustment required per label
Severe renal impairment (eGFR <30, not on dialysis)	20 mg once daily	Subcutaneous injection	Same time each day	Reduced dose — half of standard adult dose
Adults on dialysis (eGFR <30)	Not established	Not established	Not established	Insufficient information to recommend a dosage regimen
Pediatric patients (<30 kg)	Not established	Not established	Not established	Safety and effectiveness not established for this weight group
Neonates	Not approved	Not approved	Not applicable	Contains benzyl alcohol — not approved for neonates

How SS-31 works in the body

SS-31 is described in the FDA label as a mitochondrial cardiolipin binder that localizes to the inner mitochondrial membrane and improves mitochondrial morphology and function. Cardiolipin is a specialized lipid that helps support mitochondrial membrane structure and efficient energy production. In plain language, SS-31 is designed to act close to the cell's energy machinery rather than working like a stimulant. (accessdata.fda.gov)

That distinction matters. People often compare mitochondrial peptides with broader recovery-focused compounds, but these are different substances with different proposed mechanisms and evidence bases. SS-31 is not simply positioned as a general recovery peptide; its strongest regulatory footing is tied to Barth syndrome and mitochondrial dysfunction research.

Positive aspects and potential benefits of SS-31 peptide

The most important positive aspect of SS-31 is its targeted mitochondrial mechanism. By binding cardiolipin and localizing to the inner mitochondrial membrane, elamipretide is designed to support mitochondrial structure and function, which may be especially relevant in conditions where mitochondrial dysfunction contributes to muscle weakness or poor cellular energy handling. (accessdata.fda.gov)

For eligible Barth syndrome patients, the approved indication is to improve muscle strength. The FDA approval was granted under the accelerated approval pathway based on improvement in knee extensor muscle strength, an intermediate clinical endpoint, with continued approval potentially dependent on confirmatory evidence. This makes the benefit meaningful, but also specific: it does not automatically prove broad anti-aging, athletic performance, fatigue, or wellness claims. (fda.gov)

Potential benefits discussed in the research literature include support for mitochondrial bioenergetics, reduced oxidative stress signaling, and improved mitochondrial stability in studied contexts. These are encouraging areas, especially for rare disease and mitochondrial medicine, but they should be framed as evidence-informed possibilities rather than guaranteed outcomes for every user. (pmc.ncbi.nlm.nih.gov)

Why dose timing and administration details matter

The labeled medication is injected under the skin once daily, and the dose should be taken at the same time each day. The FDA label says injections may be given in the abdomen or outer thigh, with daily rotation of injection sites, and the product should not be injected into tender, bruised, red, hard, scarred, or stretch-marked skin. (accessdata.fda.gov)

These administration details are not minor. Subcutaneous medications can cause local irritation, and rotating sites helps reduce repeated stress on one area. The label also notes that vials should be inspected before use and not used if the solution is cloudy or contains particulate matter.

A practical injection routine usually includes:

1. Confirm the dose and timing with the prescribing clinician.

2. Inspect the medication as instructed.

3. Choose an appropriate abdomen or outer-thigh injection site.

4. Rotate away from yesterday's injection area.

5. Avoid irritated, bruised, hardened, or damaged skin.

6. Track dose time, site, and any reaction.

7. Report unusual symptoms promptly.

Safety considerations before using SS-31

The most common adverse reactions listed in the FDA label are injection site reactions, including redness, pain, itching, induration, bruising, and urticaria. Hypersensitivity reactions, including serious allergic reactions requiring emergency medical intervention, have also been reported, with symptoms that may include skin and respiratory manifestations. (accessdata.fda.gov)

Renal function is another key safety issue because elamipretide and its metabolites are recovered in urine, and exposure increases in renal impairment. This is why the label gives a reduced adult dose for severe renal impairment not requiring dialysis and states that there is insufficient information for adults on dialysis.

Before discussing any SS-31 peptide dosage with a healthcare professional, it is helpful to prepare:

• Current medications and supplements
• Kidney function history or recent lab results
• Allergy history, especially prior injection reactions
• Pregnancy or lactation considerations, if relevant
• Any history of severe skin reactions
• The exact product source, concentration, and labeling if already obtained

Common mistakes with SS-31 peptide dosing

One common mistake is treating a dosage chart as a personalized prescription. A chart can help readers understand labeled dosing, but it cannot account for diagnosis, kidney function, age, product quality, other medications, or the reason someone is considering the peptide.

Another mistake is assuming that more peptide means more benefit. The FDA label identifies a specific once-daily dose for a specific patient population, along with a lower dose for a defined renal impairment group. Increasing the dose outside medical guidance may increase risk without improving results.

A third mistake is stacking peptides based on unrelated benefits. Combining compounds can make side effects harder to interpret and may introduce unknown risks. If a clinician recommends a treatment plan, each component should have a clear purpose and monitoring strategy.

The practical takeaway

The clearest evidence-based answer is that labeled SS-31 peptide dosage for eligible Barth syndrome patients weighing at least 30 kg is 40 mg subcutaneously once daily, with a 20 mg once-daily dose for adults with severe renal impairment who are not on dialysis. For everyone else, especially those exploring SS-31 for wellness, fatigue, longevity, or performance, the responsible next step is not self-dosing but a medical conversation grounded in diagnosis, lab context, and product quality.

SS-31 is an important mitochondrial peptide with a promising and increasingly defined clinical role. Its benefits are most credible when discussed in the context of mitochondrial function, Barth syndrome, and supervised care. Use dosage charts as educational tools, not shortcuts, and let qualified medical guidance shape any real-world decision.

Related Peptides

Frequently Asked Questions

Related Guides